VARIABLE EFFECT OF URSODEOXYCHOLIC ACID ON CYCLOSPORINE ABSORPTION AFTER ORTHOTOPIC LIVER-TRANSPLANTATION

被引：10

作者：

ALQUAIZ, MN ^{[1
]}

OGRADY, JG ^{[1
]}

TREDGER, JM ^{[1
]}

WILLIAMS, R ^{[1
]}

机构：

[1] KINGS COLL HOSP & KINGS COLL SCH MED & DENT,INST LIVER STUDIES,LONDON SE5 9RS,ENGLAND

来源：

TRANSPLANT INTERNATIONAL | 1994年 / 7卷 / 03期

关键词：

CYCLOSPORINE-A; LIVER TRANSPLANTATION; URSODEOXYCHOLIC ACID;

D O I：

10.1007/BF00327086

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

The acute effects of administering a single dose of ursodeoxycholic acid (UDCA) on cyclosporin pharmacokinetics were recorded during paired studies in twelve liver transplant recipients, six of whom were cholestatic. Cyclosporin was measured using monoclonal selective antibodies (for parent drug) and non-selective antibodies (for cyclosporin plus metabolites). UDCA resulted in more rapid absorption of cyclosporin in 8 of 12 cases (67 %) but had no effect in two patients with and two patients without cholestasis. Median t(max) did not change significantly after UDCA (3.0 vs 4.0 h without UDCA) and only 7 of 12 patients (58 %) showed a rise in the amount of cyclosporin absorbed over 24 h with the AUC not having changed significantly (median 4527 vs 4979 mug.h.l-1 without UDCA). Median C(max) and C24 also increased only marginally following UDCA administration (616 vs 587 mug.l-1 and 87 vs 58 mug.l-1 without UDCA, respectively). In the cholestatic patients, median AUC was 50 % smaller (3223 vs 6439 mug.h-l-1) and median t1/2 a was 100 % longer (1.58 vs 0.8 h) than in patients without cholestasis. There was no consistent improvement in cyclosporin pharmacokinetics in the cholestatic patients following UDCA, although the significantly elevated ratio of non-selective: selective AUC measurements (median 4.8 vs 2.7) fell markedly in the two most severely affected, possibly as a result of an increased clearance of cyclosporin metabolites by choleresis.

引用

页码：190 / 194

页数：5

共 24 条

[1]

Andrews W., Iwatsuki S., Shaw B.W., Starzl T.E., Letter to the editor, Transplantation, 39, (1985)

[2]

Berden J.H.M., Hoitsma A.J., Merx J.L., Keyser A., Severe central nervous system toxicity associated with Cyclosporine, Lancet, 1, pp. 219-220, (1985)

[3]

Cakaloglu Y., Marinos G., Marsden J., Peters T.J., Willia R., Tredger J.M., Localization of cyclosporin A absorption in rat small bowel and the effect of bile, Clin Sci, 84, pp. 675-679, (1993)

[4]

Ericzon B.G., Todo S., Lynch S., Kam I., Ptachcinski R.J., Burchart G.J., van Thiel D.H., Starzl T.E., Venkataramanan R., Role of bile and bile salts on cyclosporine absorption in dogs, Transplant Proc, 19, pp. 1248-1249, (1987)

[5]

de Groen P.C., Cyclosporine and the liver: how one affects the other, Transplant Proc, 22, pp. 1197-1202, (1990)

[6]

Johnston A., Woolard R.C., Strip: an interactive computer program for the analysis of drug pharmacokinetics, J Pharmacol Methods, 9, pp. 193-200, (1983)

[7]

Kahan B.D., Kramer W.G., Wideman C., Flecher S.M., Lobert M.I., van Buren C.T., Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay, Transplantation, 41, pp. 459-464, (1986)

[8]

Kolars J.C., Awni W.D., Merion R.M., Watkins P.B., First-pass metabolism of cyclosporin by the gut, Lancet, 338, pp. 1488-1490, (1991)

[9]

Lemaire M., Fahr A., Maurer G., Pharmacokinetics of cyclosporine: interand intra-individual variations and metabolic pathways, Transplant Proc, 22, pp. 1110-1112, (1990)

[10]

Makino J., Shinizaki K., Nakagawa K., Yoshino K., Dissolution of cholesterol gallstones by long-term administration of ursodeoxycholic acid, Jpn J Gastroenterol, 72, pp. 690-702, (1975)

← 1 2 3 →